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Summary
We recently isolated a cDNA clone that encodes the melanocyte lineage-specific antigen glycoprotein 
(gp)100. Antibodies directed against gplOO are an important tool in the diagnosis of human 
melanoma. Since the gplOO antigen is highly expressed in melanocytic cells, we investigated whether 
this antigen might serve as a target for antimelanoma cytotoxic T lymphocytes (CTL). Here, 
we demonstrate that cytotoxic tumor-infiltrating lymphocytes (TIL) derived from a melanoma 
patient (TIL 1200) are directed against gplOO. HLA-A2.1 + melanoma cells are lysed by TIL 
from this patient. In addition, murine double transfectants, expressing both HLA-A2.1 and gplOO, 
are lysed by TIL 1200, whereas transfectants expressing only HLA-A2.1 are not susceptible to 
lysis. Furthermore, the HLA-A2.1* melanoma cell line BLM, which lacks gplOO expression 
and is resistant to lysis, becomes susceptible after transfection of gplOO cDNA. Finally, HLA- 
A2.1+ normal melanocytes are lysed by TIL 1200. These data demonstrate that the melanocyte 
differentiation antigen gplOO can be recognized in the context of HLA-A2.1 by CTL from a 
melanoma patient. GplOO may therefore constitute a useful target for specific immunotherapy 
against melanoma, provided that no unacceptable cytotoxicity towards normal tissue is observed.
T he melanocyte lineage-specific antigens recognized by 
mAb NKI-beteb are among the best diagnostic markers 
for human melanoma available to date (1). NKI-beteb reacts 
with melanoma cells throughout tumor development and does 
not cross-react with other tumor cell types or normal cells, 
except for melanocytes and pigmented cells in the retina. The 
antigen recognized by mAb NKI-beteb is an intracellular gly­
coprotein of approximately 100 kD (gplOO) (1). Recently, 
we isolated a cDNA clone termed gpl00-cl, which not only 
confers reactivity to mAb NKI-beteb, but also to two other 
mAbs used in diagnosis of malignant melanoma, HMB-50 
and HMB-45 (2). Characterization of the gpl00-cl cDNA 
revealed that gplOO is a type I transmembrane glycoprotein 
highly homologous to another melanocyte-specific protein
Pmell7 (Adema, G. J., A. J. de Boer, A. M. Vogel, W. A. M. 
Loenen, and C. G. Figdor, manuscript submitted for publi­
cation).
Although the mAbs recognizing gplOO are widely used 
for diagnostic purposes, they are less well applicable for ther­
apeutic use since gplOO is predominantly expressed intracel­
lular ly. However, it has now been clearly demonstrated that
intracellular proteins can be processed and presented as pep­
tides in association with MHC molecules to T lymphocytes 
(3, 4). Therefore, the gplOO antigen is a potential target for 
cellular immune responses against melanoma. CTLs recog­
nizing melanoma tumor cells in a TCR-dependent and MHC- 
restricted manner have been isolated from tumor-bearing 
patients (for a review see reference 5). These CTLs often dis­
play ero ss-reactivity with allogeneic HLA-A2.1-matched mela­
nomas, implying that shared melanoma antigens presented 
in the context of HLA-A2.1 are recognized (6 , 7). Recently, 
it has been reported that some CTLs not only react with 
melanoma tumor cells, but also w ith normal melanocytes, 
suggesting recognition of differentiation antigens expressed 
by melanocytes (8).
Several approaches have been followed to unravel the na­
ture of the antigens recognized by antimelanoma CTLs (9, 
10). However, the identity of the antigens remains largely 
unknown. So far, only a genetic approach applied by Van 
der Bruggen et al. (9) and Brichard et al. (11) resulted in the 
identification of antigens recognized by CTL (9,11). We have 
chosen to follow a reversed approach in that we focused on
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a well-defined melano cy tic antigen, the gplOO antigen, and 
investigated whether this antigen can serve as a target for 
antimelanoma CTLs.
Here, we demonstrate that the melanocyte differentiation 
antigen gplOO is specifically recognized by melanoma-de­
rived tumor-infiltrating lymphocytes (TIL) in the context of
HLA-A2.1.
Materials and Methods
Cell Culture. TILs were generated by growth of single cell sus­
pensions of metastatic melanomas with 1,000 U /m l IL2 (Cetus 
Corp., Emeryville, CA) and were grown as was described previ­
ously (7). Melanoma lines Mel 397 and Mel 624 were obtained 
and grown as was reported previously (7). HLA~A2 ,1+ melanoma 
lines MeWo (12) and BLM (13) and murine P815 transfectants were 
grown in DMEM (Gibco, Paisley, Scotland, UK) plus 7.5% heat- 
inactivated FCS (Gibco). JY, K562, and murine EL4 transfectants 
were cultured in IMDM (Gibco) plus 7.5% FCS. Murine cells were 
grown in the presence of 5 x 10“5 M j8 -ME, and all media con­
tained antibiotics. Isolation of normal melanocytes from foreskin 
was performed by the method of Eisinger and Marko (14) with 
modifications as described previously (15). Melanocytes from pas­
sages two to three were used in chromium release assays.
D N A  Constructs and Transfection. Plasmid pBJlgplOOneo was 
obtained by cloning the EcoRI fragment of the X gpl00-cl cDNA  
clone (2) in the coding orientation in the polylinker of pBJl-neo 
(16). Plasmid pBA2 containing a genomic fragment encoding HLA- 
A2.1 and human ft-microglobulin was kindly provided by E. J. 
Baas (The Netherlands Cancer Institute, Division of Biochemistry, 
Amsterdam, the Netherlands). Plasmid pGK-hyg contains the 
hygromycin phosphotransferase gene (17). For the introduction of 
the HLAA2.1 and ft-microglobulin genes, EL4 cells were trans­
fected with 18 fxg of pBA2 and 2 ¿¿g of pGK-hyg D N A  according 
to the calcium phosphate coprecipitation procedure (18) using 
Calciumphosphate Transfection Systems (GIBCO BRL, Gaithers­
burg, MD). 24 h after transfection, 500 pg/m \ hygromycin B 
(Calbiochem-Novabiochem Corp., La Jolla, CA) was added to the 
medium for selection of stable transfectants. HLA-A2 .1* gplOO + 
EL4 cells were obtained by transfection of stable HLA-A2.1+ EL4 
clones with 20 fxg of pBJl-gpl00 D N A  and were selected with 
500 ftg/ml hygromycin B and 1 mg/ml G418 (Gibco). BLM cells 
were transfected with 20 p g of pBJl-gpl00neo D N A  by calcium 
phosphate coprecipitation and were selected with 1 mg/ml G418. 
P815 A2.1 and P815 A2.1/gplOO cells were kindly provided by P. 
Coulie (Ludwig Institute, Brussels, Belgium).
mAb and Flow Cytometry. Phenotypic analysis of melanomas, 
transfectants, and normal melanocytes was performed by indirect 
immunofluorescence followed by flow cytometry using a FACScan® 
(Becton Dickinson & Co., Mountain View, CA). Purified anti-gplOO 
mAb NKI-beteb (1), and anti-HLA-A2 mAbs BB7.2 (culture su­
pernatant) (19) and MA2.1 (ascites 1:500 dilution) (20) were used 
as primary reagents. FITC-conjugated GAM-IgG-F(ab')2 (Zymed 
Laboratories, Inc., S. San Francisco, CA) was used for the second 
incubation. For the detection of the intracellular gplOO antigen 
cells were permeabilized in 0 .01% digitonin and were subsequently 
fixed in 1% paraformaldehyde.
Chromium Release Assay. Chromium release assays were per­
formed as described previously (7). Briefly, 106 target cells were 
incubated with 100 jxCi Na51Cr0 4  (Amersham International, 
Bucks, UK) for 1 h. Various amounts of effector cells were then 
added to 2 x 103 target cells in triplicate wells of U-bottomed
micro titer plates (Costar, Badhoevedorp, The Netherlands) in a final 
volume of 150 p\. After 5 h of incubation, part of the supernatant 
was harvested and its radioactive content measured. Target cells 
were incubated for 48 h with 50 U/m l human (Boehringer, Ingel­
heim, Germany) or mouse recombinant IFN-7  (TNO, Rijswijk, 
The Netherlands) before use in chromium release assays.
Results and Discussion
In search of gp 100-specific CTLs we focused on HLA-A2.1 
as a restriction element because of its widespread occurrence 
in Caucasians and its presumptive dominant role in CTL re­
activity against melanoma. A HLA-A2.1+ TIL line, TIL 
1200, was used for this study. This TIL line expresses TCR- 
a/ ß ,  CD3, and CD8 (data not shown).
HLA-A2.1-restricted Killing of Melanoma Tumor Cells by TIL 
1200 Corresponds to gplOO Expression. Cytolytic activity of 
TIL 1200 was analyzed using a panel of human melanoma 
cell lines. As shown in Fig. 1, TIL 1200 efficiently lysed HLA- 
A2.1+ Mel 624 and MeWo melanoma tumor cells, which 
both express gplOO, whereas no reactivity towards HLA- 
A2.1" gplOO+ Mel 397 cells was seen. It is interesting to 
note that we observed that HLA-A2.1+ BLM melanoma 
cells also are resistant to lysis by TIL 1200 (Fig. 1), Previ­
ously, we have shown that BLM cells lack the expression of 
the gplOO antigen, both at the protein and at the mRNA 
level (2). Furthermore, HLA-A2.1* EBV-transformed B 
cells (JY), which also lack gplOO expression, and K562 cells, 
were not lysed by TIL 1200 (data not shown). Together, these 
data demonstrate that TIL 1200 displays HLA-A2.1-restricted 
killing which correlates with gplOO expression.
TIL 1200 Recognizes HLA-A2.Î+ gpl00+ Transfectants. 
To explore whether TIL 1200 recognized a gplOO-derived 
peptide in the context of HLA-A2.1, we cotransfected mu­
rine EL4 cells with a genomic fragment encoding HLA-A2.1 
together with a plasmid conferring hygromycin resistance. 
Stable hygromycin-resistant transfectants were selected and 
analyzed for HLA-A2.1 surface expression by flow cytom­
etry. EL4 cells expressing HLA-A2.1 (EL4 A2.1) were sub­
sequently transfected with pBJl-gpl00neo, which encodes 
gplOO and confers resistance to G418. Stable transfectants were 
selected and were screened for gplOO expression using mAb
Figure 1. HLA-A2.1-restricted 
killing of gplOO+ melanoma 
tumor cells by TIL 1200. Lysis of 
chromium-labeled cells was mea­
sured after 5 h. All melanoma cell 
lines except BLM express the 
gplOO antigen. One representative 
experiment out of three.
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Figure 2. Lysis of HLAA2.1+- gplOO+ transfectants by TIL 1200. Murine EL4 and P815 cells were transfected with both gplOO and HLA-A2.1 
DNA, and human BLM cells were transfected gplOO DNA as described in Materials and Methods. Isolated clones were tested for sensitivity to lysis 
by TIL 1200. (^ 4 and B) Representative examples of experiments performed with four individual EL4 A2.1/gpl00 and P&L5 A2.1/gpl00 clones. (C) 
One experiment out of three, using BLM gplOO clones H2.3 and 5A3.
NKI-beteb (EL4 A2.1/gpl00). In collaboration with P. Coulie 
a similar panel of transfectants was generated in murine P815 
cells (P815 A2.1 and P815 A2.1/gpl00). Using these murine
transfectants as target cells in chromium release assays, we 
clearly observed gplOO specific lysis by TIL 1200 (Fig* 2, A  
and B). The percent specific lysis (25-35%, E/T 30:1) of 
murine EL4 A2.1/gpl00 and P815 A2.1/gpl00 transfectants 
by TIL 1200 was somewhat lower compared with that 
observed with the HLA-A2.1* gplOO+ human melanoma 
cells (45-60%, E /T  30:1). This difference may be explained 
by nonmatched accessory molecules between human TILs 
and murine transfectants. To overcome this we introduced 
the gplOO antigen into human HLA-A2.1 + gplOO” BLM 
melanoma cells by transfection of pBJl-gpl00neo. Stable BLM
Lysis of HLA-A2.1'l\  gplOO + melanocytes rules out the 
possibility that TIL 1200 recognizes a peptide epitope of gplOO, ' 
mutated in melanoma tumor cells. This is further demon“ 
strated by the fact that TIL 1200 is reactive with several al­
logeneic HLA-A2.1 matched, gplOO+ melanoma tumor 
lines. We therefore conclude that TIL 1200 recognizes a non­
mutated peptide derived from the melanocyte differentiation 
antigen gplOO expressed by melanoma tumor cells, as well 
as by normal melanocytes.
Furthermore, our data show that gplOO can be immuno­
genic, suggesting that melanocyte differentiation antigens may 
serve as tumor rejection antigens. This hypothesis is strength­
ened by: (a) the finding that antibodies directed against this 
type of antigens (e.g., gp75) are present in the serum of rnela-
gplOO clones were tested in chromium release assays using noma patients (21, 22); (h) the recent observation that sev-
TIL 1200. As shown in Fig. 2 C, BLM gplOO clones H2.3 
and 5A3 were as sensitive to lysis by TIL 1200 as Mel 624 
and MeWo cells which express the gplOO antigen endoge-
eral antimelanoma CTLs display cross-reactivity with normal 
melanocytes (8); and (c) the identification of the melanocyte 
lineage-specific tyrosinase protein as a target for antimela-
nously. The gplOO specificity of TIL 1200 was further demon- noma CTLs (11). Immuno genici ty of melanocyte differenti- 
strated by the absence of lysis of G418-resistant BLM cells 
not expressing gplOO, excluding the possibility that neomycin- 
derived peptides are recognized (data not shown). We con­
clude from these data that TIL 1200 recognizes a gplOO-derived 
peptide presented in HLA-A2.1.
HLA-A2A + Normal Melanocytes Are Lysed by TIL 1200.
Since gplOO is expressed in all cells of the melanocytic lin­
eage, one would predict that normal melanocytes are also rec­
ognized by TIL 1200. To investigate this, short-term cultures 
of HLA-A2.1+ and HLA-A2.1~ normal melanocytes were 
tested for lysis by TIL 1200. Melanocytes used in this study 
all expressed the gplOO antigen to a similar extent (data not 
shown). HLA-A2.1+ melanocytes were efficiently lysed, 
whereas HLA-A2.1" melanocytes were resistant to lysis by 
TIL 1200 (Fig. 3). These results demonstrate that TIL 1200 
is also reactive with gplOO-derived peptides presented in HLA- 
A2.1 by normal melanocytes.
E/T ratio
-¿s—
melanocytes 1 
melanocytes 2 
melanocytes 3 
melanocytes 4
HLA A2.1+ 
HLA A2.1+ 
HLA A2.1- 
HLA A2.1-
F igure  3. Lysis of HLA-A2.1* 
normal melanocytes by TIL 1200’. 
Short-term cultures of foreskin- 
derived melanocytes were tested 
for sensitivity to lysis by TIL 1200. 
Expression of HLA-A2.1 was ana­
lyzed by flow cytometry using
mAbs BB7.2 (19) and MA2.1 
(20).
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ation antigens may also explain the clinical observation that 
melanoma patients often display local depigmentation of their 
skin (23). The occurrence of local depigmentation in mela­
noma patients has been reported to correlate with prolonged 
survival (23) and may result from the destruction of melano­
cytes as a consequence of an immune response directed against 
melanocyte differentiation antigens (24), Other clinical data, 
indicating that vitiligo (local depigmentation of the skin) is 
associated with improved survival of melanoma patients (25), 
are in line with this hypothesis. TILs have been shown to 
mediate regression of metastatic melanoma in patients treated 
with TILs plus IL-2 (26). O f particular interest is the fact 
that therapy with TIL 1200 was associated with objective 
tumor regression in the autologous patient (Rosenberg, S. A.,
unpublished data), suggesting that CTLs directed against 
melanocyte differentiation antigens can cause tumor regres­
sion in vivo.
Since melanocyte differentiation antigens such as gplOO are 
widely expressed in melanoma tumor cells, they may consti­
tute a useful target for specific immunotherapy against mela­
noma. Although no unwanted toxicity was observed in the 
autologous patient upon TIL 1200 treatment, adverse side 
effects upon gplOO immunization, such as the destruction 
of normal melanocytic cells and retinal pigment epithelium 
cells, remain a possibility and require further study in animal 
models. Furthermore, it will be important to determine how 
widely T cell-mediated gplOO reactivity is observed in mela­
noma patients.
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